Moclobemide in pregnancy

Jk, Rybakowski

doi:10.1055/s-2001-15185

Cited by 16 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no fetal adverse effects were found in the offspring of rats treated with tranylcypromine (Gracious and Wisner, 1997) or moclobemide (Rybakowski, 2001). Scant information is available regarding the teratogenic potential of MAOIs in humans.…”

Section: B Monoamine Oxidase Inhibitorsmentioning

confidence: 98%

“…However, the small sample size, the lack of description of the type of abnormalities, and the inclusion of isoniazid in the exposed group limits interpretation of these results. On the other hand, further case reports failed to demonstrate any positive significant association between the prenatal exposure to phenelzine, tranylcypromine, and moclobemide and infant malformations (Gracious and Wisner, 1997;Rybakowski, 2001).…”

Section: B Monoamine Oxidase Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects

Costa

Steardo

Cuomo

2004

Pharmacological Reviews

View full text Add to dashboard Cite

Section: B Monoamine Oxidase Inhibitorsmentioning

confidence: 98%

Section: B Monoamine Oxidase Inhibitorsmentioning

confidence: 99%

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects

Costa

Steardo

Cuomo

2004

Pharmacological Reviews

View full text Add to dashboard Cite

“…Recently Reversible Inhibitors of Monoamine oxidase A (RIMAs) such as moclobemide that diminish the potential for food and drug interactions have become available in Europe. A case report showed that Moclobemide treatment had no adverse effects on the fetus of a woman who took moelobemide throughout pregnancy at a doseof300mg/day (49).…”

Section: Monoamine Oxidase Inhibitors (Maois)mentioning

confidence: 99%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

About 20% of pregnant women experience clinical depression. Inadequate treatment of depression has been associated with adverse outcomes in the mother as well as the newborn. Clinicians are often uncertain about pharmacological interventions to treat depressed pregnant women due to concerns regarding fetal exposure to medications. Moreover newer antidepressants with different pharmacological profiles and little data on fetal risk continue to be introduced at a brisk pace. Accumulating data from pharmaceutical registries, cohort studies, toxicology centers, some prospective studies, and case series have permitted certain guidelines for antidepressant use during pregnancy. We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy.

show abstract

“…The course of pregnancy was healthy and natural delivery was uneventful. The psychomotoric and somatic development of the child within the first 14 months of life was normal (195).…”

Section: Pregnancymentioning

confidence: 99%

Moclobemide: Therapeutic Use and Clinical Studies

Bonnet¹

2003

CNS Drug Reviews

205

100

View full text Add to dashboard Cite

Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a growing evidence that moclobemide is not inferior to other antidepressants in the treatment of subtypes of depression, such as dysthymia, endogenous (unipolar and bipolar), reactive, atypical, agitated, and retarded depression as with other antidepressants limited evidence suggests that moclobemide has consistent long-term efficacy. However, more controlled studies addressing this issue are needed. For patients with bipolar depression the risk of developing mania seems to be not higher with moclobemide than with other antidepressants. The effective therapeutic dose range for moclobemide in most acute phase trials was 300 to 600 mg, divided in 2 to 3 doses. While one controlled trial and one long-term open-label study found moclobemide to be efficacious in social phobia, three controlled trials subsequently revealed either no effect or less robust effects with the tendency of higher doses (600 -900 mg /d) to be more efficacious. Two comparative trials demonstrated moclobemide to be as efficacious as fluoxetine or clomipramine in patients suffering from panic disorder. Placebocontrolled trials in this indication are, however, still lacking.A relationship between the plasma concentration of moclobemide and its therapeutic efficacy is not apparent but a positive correlation with adverse events has been found. Dizziness, nausea and insomnia occurred more frequently on moclobemide than on placebo. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri-or heterocyclic antidepressants. Gastrointestinal side effects and, espe-97

show abstract

Moclobemide in pregnancy

Cited by 16 publications

References 6 publications

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects

Pharmacotherapy of Depression in Pregnancy

Moclobemide: Therapeutic Use and Clinical Studies

Contact Info

Product

Resources

About